Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.

Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...

Sino Biopharmaceutical has struck a licensing deal with AstraZeneca for a chronic respiratory disease treatment and obtained commercialization rights for two GSK treatments in China, as global ...

Pfizer PFE and AstraZeneca AZN are global pharmaceutical leaders with a strong presence in oncology. For Pfizer, oncology is ...

AstraZeneca (LSE:AZN) is back in focus after a recent pullback, with the stock down about 5% over the past month and over the past 3 months, prompting investors to reassess its current valuation. See ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to ...

Texas Attorney General Ken Paxton announced Monday that his office has reached a settlement with AstraZeneca Pharmaceuticals ...

Texas secures nearly 34 million dollar settlement with AstraZeneca over allegations of illegal kickbacks tied to Medicaid ...

AstraZeneca has some exciting things going on... AstraZeneca currently has three programs targeting diabetes and obesity care. During the ObesityWeek conference earlier this month, management provided ...

AstraZeneca's Clean Heat Program is turning industrial heat decarbonization into a hedge against energy volatility — and a core business strategy.

Shares in pharmaceutical giant AstraZeneca (LSE: AZN) took a hit last month after the head of the company’s Chinese business was detained. Reports suggested the Chinese government was looking into ...